share_log

Altimmune | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Altimmune | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Altimmune | S-8：员工福利计划证券登记
美股sec公告 ·  03/27 16:15
Moomoo AI 已提取核心信息
Altimmune, Inc., a biopharmaceutical company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on March 27, 2024. This filing pertains to the registration of an additional 3,055,006 shares of common stock under the company's 2017 Omnibus Incentive Plan. The plan allows for an automatic annual increase in the number of shares available for issuance, which is determined on January 1 of each year, based on a set formula. The newly registered shares are of the same class as those previously registered under the 2017 Plan. Altimmune's CEO, Dr. Vipin K. Garg, along with other executives and directors, have signed the Registration Statement, indicating their compliance with the requirements for filing on Form S-8.
Altimmune, Inc., a biopharmaceutical company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on March 27, 2024. This filing pertains to the registration of an additional 3,055,006 shares of common stock under the company's 2017 Omnibus Incentive Plan. The plan allows for an automatic annual increase in the number of shares available for issuance, which is determined on January 1 of each year, based on a set formula. The newly registered shares are of the same class as those previously registered under the 2017 Plan. Altimmune's CEO, Dr. Vipin K. Garg, along with other executives and directors, have signed the Registration Statement, indicating their compliance with the requirements for filing on Form S-8.
生物制药公司Altimmune, Inc. 已于2024年3月27日向美国证券交易委员会（SEC）提交了S-8表格的注册声明。该文件涉及根据公司2017年综合激励计划另外注册3,055,006股普通股。该计划允许每年自动增加可供发行的股票数量，该数量根据设定的公式在每年1月1日确定。新注册的股票与先前根据2017年计划注册的股票属于同一类别。Altimmune的首席执行官Vipin K. Garg博士以及其他高管和董事签署了注册声明，表示他们遵守了提交S-8表格的要求。
生物制药公司Altimmune, Inc. 已于2024年3月27日向美国证券交易委员会（SEC）提交了S-8表格的注册声明。该文件涉及根据公司2017年综合激励计划另外注册3,055,006股普通股。该计划允许每年自动增加可供发行的股票数量，该数量根据设定的公式在每年1月1日确定。新注册的股票与先前根据2017年计划注册的股票属于同一类别。Altimmune的首席执行官Vipin K. Garg博士以及其他高管和董事签署了注册声明，表示他们遵守了提交S-8表格的要求。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息